Compare WING & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | CELC |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.2B |
| IPO Year | 2015 | 2017 |
| Metric | WING | CELC |
|---|---|---|
| Price | $153.21 | $56.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 13 |
| Target Price | ★ $184.92 | $150.85 |
| AVG Volume (30 Days) | ★ 1.4M | 935.0K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 67.84 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $696,853,000.00 | N/A |
| Revenue This Year | $7.16 | N/A |
| Revenue Next Year | $14.63 | $1,921.71 |
| P/E Ratio | $44.68 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $95.82 | $53.54 |
| 52 Week High | $302.80 | $151.02 |
| Indicator | WING | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 34.05 |
| Support Level | $139.01 | $53.54 |
| Resistance Level | $177.19 | $72.76 |
| Average True Range (ATR) | 9.46 | 4.26 |
| MACD | -2.44 | -0.82 |
| Stochastic Oscillator | 25.28 | 10.75 |
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across over 10 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 stores, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.